Other
23 Authors
- Christian M,
- Yu X,
- Nilsson SK,
- Chen R,
- Qu X,
- Oorschot V,
- Zhang J,
- Tang H,
- Kerr PG,
- Chi H,
- Chen W,
- Puelles VG,
- Zhu D,
- Ren Y,
- Nikolic-Paterson DJ,
- Sun YBY,
- Chen Q,
- Fan J,
- Li S,
- Wu Z,
- Bertram JF,
- Crawford S,
- Li J
| First Author | Li J | Year | 2020 |
| Journal | EMBO Rep | Volume | 21 |
| Issue | 2 | Pages | e48781 |
| PubMed ID | 31916354 | Mgi Jnum | J:287918 |
| Mgi Id | MGI:6390372 | Doi | 10.15252/embr.201948781 |
| Citation | Li J, et al. (2020) Smad4 promotes diabetic nephropathy by modulating glycolysis and OXPHOS. EMBO Rep 21(2):e48781 |
| abstractText | Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease. TGF-beta1/Smad3 signalling plays a major pathological role in DN; however, the contribution of Smad4 has not been examined. Smad4 depletion in the kidney using anti-Smad4 locked nucleic acid halted progressive podocyte damage and glomerulosclerosis in mouse type 2 DN, suggesting a pathogenic role of Smad4 in podocytes. Smad4 is upregulated in human and mouse podocytes during DN. Conditional Smad4 deletion in podocytes protects mice from type 2 DN, independent of obesity. Mechanistically, hyperglycaemia induces Smad4 localization to mitochondria in podocytes, resulting in reduced glycolysis and oxidative phosphorylation and increased production of reactive oxygen species. This operates, in part, via direct binding of Smad4 to the glycolytic enzyme PKM2 and reducing the active tetrameric form of PKM2. In addition, Smad4 interacts with ATPIF1, causing a reduction in ATPIF1 degradation. In conclusion, we have discovered a mitochondrial mechanism by which Smad4 causes diabetic podocyte injury. |
